Mylotarg originally secured accelerated approval in 2000 as a standalone treatment for older patients with CD33-positive AML who had experienced a relapse, but was voluntarily withdrawn after subsequent confirmatory studies failed to verify clinical benefit and demonstrated safety concerns, including a high number of deaths.
Friday’s approval includes a lower recommended dose, a different dosing schedule and a new patient population, the FDA said.
More about: #FDA #leukaemia
